Clinical efficacy of ofloxacin in lower respiratory tract infections. A multicentre study.
A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections. 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400 mg (245 patients), 600 mg (211) or 800 mg (211). The mean duration of treatment was 8.77 +/- 2.62 days. Satisfactory overall clinical results (i.e. cured or improved) were obtained in 612 of 667 patients (91.8%). Eradication of pathogens was achieved for 279 of 354 isolated strains (78.8%). Side effects were observed in 31 patients and consisted of gastrointestinal disturbance (22), skin rash (1), neurological disturbance (3) and others (5). No significant alteration of haematological parameters was reported.
Grassi
C
C
Institute of Respiratory Diseases, University of Pavia.
Gialdroni Grassi
G
G
Mangiarotti
P
P
D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015242:Ofloxacin; D010078:Oxazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D000890:Anti-Infective Agents; D010078:Oxazines; D015242:Ofloxacin